J&J’s Cerenovus launches global thrombectomy registry

Johnson & Johnson‘s (NYSE:JNJ) Cerenovus said today that it launched a new registry aiming to collect and analyze stroke-inducing blood clots removed with the company’s Embotrap II revascularization device.

The Irvine, Calif.-based company touted the Excellent registry as the single largest global registry of its kind to date, looking to enroll up to 1,000 ischemic stroke patients across 50 locations in the U.S. and Europe. Investigators in the trial will collect and analyze clots removed to explore how different characteristics, including size, composition and density may affect outcomes, the company said.

In addition to the registry launch, Cerenovus said that it developed and recently won CE Mark approval in the European Union for its Geometric Clot Extractor revascularization system, a novel device intended to retrieve various thrombus types. The approval came based on a controlled study prior to the launch exploring its clinical utility and potential advantages over existing tech.

“This is a landmark registry study that will provide real-world data on the Embotrap II device while advancing the scientific community’s understanding of how variations in blood clots correlate with treatment and outcomes. We believe thoughtful and extensive research into the science of blood clots is the key to developing the most effective endovascular treatments and bringing its benefits to the greatest number of stroke patients. We are excited by both the clinical insights the Excellent Registry will provide and the possibilities for GCE in helping to bring the benefits of mechanical thrombectomy to difficult to treat stroke patients.We have a deep commitment to meaningful innovation through the development of evidence-based solutions that give patients the best chance for a high quality of life after stroke,” Cerenovus prez Daniella Cramp said in a press release.

In August, Cerenovus said that it won CE Mark approval in the European Union for its Bravo flow diverter designed to treat intracranial aneurysms.

The post J&J’s Cerenovus launches global thrombectomy registry appeared first on MassDevice.

from MassDevice https://ift.tt/2QNbvx6